Forecasts already pointed to Pfizer closing a great 2021, and it has done so, according to the results for last year made public by the pharmaceutical company on Tuesday. The American company obtained a net profit of US $ 21,980 million and revenue of US$81.29 billion in 2021, thanks mainly to its vaccine against covid-19.
BNT162b2 or Comirnaty, commercial name of the vaccine, accounted for 45% of Pfizer’s revenue last year, dwarfing any other drug in the company’s vast portfolio. Pfizer, which developed the vaccine in cooperation with the German biotech company BioNTech, manufactured more than 3 billion doses of the mRNA vaccine last year, which ended up providing $36.8 billion to the company’s record revenue.
By 2022, the US multinational anticipates US$32 billion in sales of its Comirnaty vaccine, in addition to US$22 billion in sales of Paxlovid, its oral antiviral drug against covid-19. Both estimates are based on the contracts that the laboratory had signed at the end of January, so the figures could be adjusted upwards over the course of the year.
